Advancing Cancer Treatment with Brilliant Chemistry:
‍Learn About Zentalis' Clinical-Stage Oncology Therapies

Known cancer biology.
Deliberate medicinal chemistry.
Improving patient lives.

About Zentalis

Improving Patient lives

We are a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers.

Learn More

News

Read more

Pipeline

Compound
Indication
Trial Name + Development Approach
Phase 1
Phase 1b
Phase 2
Phase 3

Azenosertib WEE1 Inhibitor

Gynecologic malignancies
Other Tumor types
Platinum Sensitive Ovarian Cancer
Planned trial in 1L maintenance setting*
Phase 3
Platinum Resistant Ovarian Cancer
DENALI (ZN-c3-005)
Monotherapy
Phase 2
PARPi Resistant Ovarian Cancer
MAMMOTH (ZN-c3-006)
Azenosertib monotherapy, or with niraparib
Phase 2
Uterine Serous Carcinoma
TETON (ZN-c3-004)
Monotherapy, FDA Fast Track Designation
Phase 2
Platinum Resistant Ovarian Cancer
ZN-c3-002
Azenosertib + multiple chemo backbones
Phase 1b
Solid Tumors
ZN-c3-001
Monotherapy
Phase 1b
Osteosarcoma
ZN-c3-003
Azenosertib + gemcitabine
Phase 1
BRAF Mutant Colorectal Cancer
ZN-c3-016
Azenosertib + encorafenib and cetuximab
Phase 1
Pancreatic Cancer
Azenosertib + gemcitabine
Phase 1
Breast Cancer
ZAP-IT
Azenosertib + carboplatin + pembrolizumab
Phase 1

*Updated guidance to be provided following resolution of clinical hold

Learn More

Join Zentalis

Be part of our vibrant team of dedicated professionals with the common goal of helping cancer patients and make a lasting impact.

Explore Careers